Therapy With an Oxytocin Adjunct for Major Depression

Depressive Disorder Clinical Trial

— TOAD2015  

Official title:

Combined Use of Intranasal Oxytocin and Interpersonal Psychotherapy for the Treatment of Major Depressive Disorder (MDD): A Randomized Controlled Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02405715
• Other study ID #: CIHR-12678
• Status: Completed
• Phase: Phase 2
• Start date: February 2015
• Est. completion date: August 2016

Study information

• Verified date: July 2021
• Source: Concordia University, Montreal
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study evaluates the addition of intranasal oxytocin to the treatment of Major Depression using interpersonal psychotherapy. Half of the participants will receive a placebo adjunct to interpersonal psychotherapy, and the other half will receive oxytocin.

Description:

Depression is a debilitating mental health condition that carries great consequences for both the individual and society. Crucially, at least one third of depressed patients do not respond to existing interventions and relapse rates are high, alerting scientists to the need to explore possible adjunctive treatments and novel therapeutic targets. In this regard, research on the use of oxytocin in the treatment of depression is promising.

It is well documented that interpersonal stress predicts the onset of depression, and that social isolation is a symptom of psychological distress that can leave patients with a poor prognosis for recovery. Therapeutic interventions focused on the alleviation of social conflict and strengthening of social bonds (i.e. Interpersonal Psychotherapy; IPT) show greater efficacy for the treatment of depression than other psychological interventions (NIMH Treatment of Depression Collaborative Research Program; Elkin et al. 1984). It has been posited that oxytocin, a naturally produced hormone that is involved in social-support seeking and stress-regulation, could represent a biological link between social stress and depression in adulthood. The salubrious effect of exogenous oxytocin on human social behavior is well documented: Oxytocin has been shown to make individuals feel more securely attached in their social relationships, increase their trust in others and openness to new ideas, improve their recall of specific and positive social autobiographical memories, and improve social learning. Importantly, these factors have been shown to improve the efficacy of Interpersonal Psychotherapy. Thus, It stands to reason that the use of oxytocin as an adjunct to IPT could improve its efficacy for the treatment of depression, which is an important prospect when considering that a third of patients do not respond to existing therapies.

In the proposed research project, we will conduct a Randomized Controlled Trial for the treatment of Major Depression with IPT and adjunctive oxytocin. Patients will be screened for eligibility, undergo structured psychotherapy for twelve weeks, and will be followed longitudinally for changes in quality of social functioning, interpersonal stress, psychiatric symptoms and depressive relapse. Establishing novel interventions for depression could position healthcare providers to better alleviate the burden and personal suffering caused by this disorder.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: August 2016
• Est. primary completion date: August 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria

• Current Major Depressive Episode

Exclusion Criteria

• Visual impairment

• Major medical illness [A condition that is chronic and associated with impaired functioning, distress, or frequent medical intervention), in particular, subjects with evidence or history of malignancy or any significant hematological, endocrine, cardiovascular (including any rhythm disorder), respiratory, renal, hepatic, or gastrointestinal disease

• Acute or chronic nasal diseases or obstruction

• Current (in the last month) use of any endocrine-relevant or psychotropic medication other than prescription antidepressants

• Current substance dependence or abuse

• Use of illicit drugs (stimulants, narcotics, psychedelics/hallucinogens, non-prescription medication) in the past 8 weeks

• Lifetime history of a psychosis (except if part of MDD) or pervasive developmental disorder

• Past or current comorbid axis-1 disorder except Dysthymia, Adjustment Disorder, Generalized Anxiety Disorder, Social Phobia, and Specific Phobia.

• Female Only: Females of child bearing potential cannot be pregnant or breastfeeding in order to participate in this study. They must not be planning to become pregnant, and must be willing to use appropriate contraception throughout the study.

• Female Only: To control for hormonal changes related to pregnancy, females will also be excluded if they have previously given birth.

Related Conditions & MeSH terms

• Depression
• Depressive Disorder

Intervention

Drug:
• Oxytocin nasal spray or placebo

Locations

Country	Name	City	State
Canada	Concordia University	Montreal	Quebec

Sponsors (1)

Lead Sponsor	Collaborator
Concordia University, Montreal

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Moderation by personality (NEO-PI-R)	NEO-PI-R; Moderation by extraversion	Baseline
Other	Mediation by personality (NEO-PI-R) [Change Score]	NEO-PI-R; Mediation by extraversion	Baseline up to 10 months later [Slope of Change]
Other	Moderation by attachment (ECR, AAI) [COMPOSITE SCORE]	ECR, AAI: Moderation by attachment style	Baseline
Other	Moderation by attachment (ECR, AAI) [COMPOSITE SCORE]	ECR, AAI: Mediation by attachment style	Baseline up to 10 months later [Slope of Change]
Other	Adverse Events [Average Score] COMPOSITE	In-house measure of adverse events weekly	baseline up to 4 months
Primary	Diagnostic status: Major Depressive Episode Using The SCID-IV [Change Score]	Diagnosis of Major Depressive Episode Will Be Diagnosed Using The SCID-IV	Baseline, 4 months later (following therapy)
Primary	Depressive symptoms (clinician-rated) 9Hamilton Rating Scale for Depression (HRS-D)[Change Score]	Hamilton Rating Scale for Depression (HRS-D)	Baseline, 4 months later (following therapy)
Primary	Depressive symptoms (clinician-rated) Inventory for Depressive Symptomology (IDS-C) [Change Score]	Inventory for Depressive Symptomology (IDS-C)	Baseline, 4 months later (following therapy)
Primary	Stress and social functioning (Global Axis of Functioning using the SCID-IV (GAF) [Change Score]	Global Axis of Functioning using the SCID-IV (GAF)	Baseline, 4 months later (following therapy)
Primary	Patient dropout rate [Number of sessions missed]	patient dropout rate	includes baseline up to 4 months following baseline assessment (until the end of therapy)
Primary	Depressive Symptoms (patient-rated) (Beck Depression Inventory-II (BDI-II) [Change Score]		Baseline up to 10 months later (slope of change over time)
Primary	Diagnostic status: Major Depressive Episode Using The SCID-IV [Change Score]	Diagnosis of Major Depressive Episode Will Be Diagnosed Using The SCID-IV	4 months later (following therapy) and 10 months later (6 months following therapy)
Primary	Depressive symptoms (clinician-rated) 9Hamilton Rating Scale for Depression (HRS-D) [Change Score]	Hamilton Rating Scale for Depression (HRS-D)	4 months later (following therapy) and 10 months later (6 months following therapy)
Primary	Depressive symptoms (clinician-rated) Inventory for Depressive Symptomology (IDS-C) [Change Score]	Inventory for Depressive Symptomology (IDS-C)	4 months later (following therapy) and 10 months later (6 months following therapy)
Primary	Stress and social functioning (Global Axis of Functioning using the SCID-IV (GAF) [Change Score]	Global Axis of Functioning using the SCID-IV (GAF)	4 months later (following therapy) and 10 months later (6 months following therapy)
Secondary	Stress and social functioning (clinician-rated) (UCLA Life Stress Interview - Chronic Stress Module (UCLA) [Change Score]	UCLA Life Stress Interview - Chronic Stress Module (UCLA)	Baseline, 4 months later (following therapy)
Secondary	Biological stress reactivity (Daily Diurnal Cortisol) [Change Score]	Daily Diurnal Cortisol (2 days)	Baseline, 4 months later (following therapy)
Secondary	Working alliance (clinician-rated) (Working Alliance Inventory (WAI) [Change Score]	Working Alliance Inventory (WAI)	Baseline up to 4 months later (slope of change over time)
Secondary	Social functioning (patient-rated) (Social Adjustment Scale- Self-Report (SAS-SR) + MSPSS) COMPOSITE SCORE [Change Score]	Social Adjustment Scale- Self-Report (SAS-SR) + MSPSS	Baseline up to 10 months later (slope of change over time)
Secondary	Stress (patient-rated) (Perceived Stress Scale (PSS) [Change Score]	Perceived Stress Scale (PSS)	Baseline up to 10 months later (slope of change over time)
Secondary	Anxiety (patient-rated) (Beck Anxiety Inventory (BAI) [Change Score]	Beck Anxiety Inventory (BAI)	Baseline up to 10 months later (slope of change over time)
Secondary	Therapeutic Alliance (patient-rated) (Working Alliance Inventory (WAI)	Working Alliance Inventory (WAI)	Baseline up to 4 months later (slope of change over time)
Secondary	Usefulness of Therapy (patient-rated); COMPOSITE SCORE	Measure by score on Helpful Aspects of Therapy (HAT)	Baseline up to 4 months later (slope of change over time)
Secondary	Stress and social functioning (clinician-rated) (UCLA Life Stress Interview - Chronic Stress Module (UCLA) [Change Score]	UCLA Life Stress Interview - Chronic Stress Module (UCLA)	4 months later (following therapy) and 10 months later (6 months following therapy)
Secondary	Biological stress reactivity (Daily Diurnal Cortisol) [Change Score]	Daily Diurnal Cortisol (2 days)	4 months later (following therapy) and 10 months later (6 months following therapy)